Browse Studies — Arctuva

Phase 2

A Phase 2/3, Randomized Study of Ordastobart (INBRX-106) Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma Expressing PD-L1 (HexAgon-HN)

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combi…

Head and Neck Squamous Cell Carcinoma (HNSCC)HPV-associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

Estimated

~$75 – $2,800

Actual pay is set by the research site.